Inotiv (NOTV) Expected to Announce Quarterly Earnings on Tuesday

Inotiv (NASDAQ:NOTV) is anticipated to post its Q4 2025 results before the market opens on Tuesday, December 2nd. Analysts expect Inotiv to post earnings of ($0.08) per share and revenue of $133.3550 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earningsummary page for the latest details on the call scheduled for Wednesday, December 3, 2025 at 4:30 PM ET.

Inotiv Stock Performance

Shares of NOTV stock opened at $0.80 on Tuesday. The stock has a market capitalization of $27.58 million, a PE ratio of -0.30 and a beta of 4.20. The business’s 50 day simple moving average is $1.27 and its 200 day simple moving average is $1.77. The company has a debt-to-equity ratio of 2.71, a current ratio of 1.29 and a quick ratio of 0.96. Inotiv has a one year low of $0.66 and a one year high of $6.48.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE grew its holdings in Inotiv by 5,660.0% in the third quarter. Bank of America Corp DE now owns 21,888 shares of the company’s stock worth $32,000 after purchasing an additional 21,508 shares during the period. Corient Private Wealth LLC bought a new position in shares of Inotiv during the 2nd quarter worth about $44,000. BNP Paribas Financial Markets grew its stake in shares of Inotiv by 11,118.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 48,015 shares of the company’s stock valued at $70,000 after buying an additional 47,587 shares during the period. American Century Companies Inc. increased its position in Inotiv by 16.4% in the 2nd quarter. American Century Companies Inc. now owns 41,933 shares of the company’s stock valued at $76,000 after buying an additional 5,894 shares in the last quarter. Finally, Wexford Capital LP acquired a new position in Inotiv during the 3rd quarter worth approximately $127,000. 18.17% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Inotiv in a research note on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Inotiv has an average rating of “Hold” and an average target price of $5.00.

About Inotiv

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.